论文部分内容阅读
目的探讨布拉酵母菌(亿活)佐治儿童幽门螺杆菌(Hp)感染的临床效果和安全性。方法选取2013年4月-2014年10月Hp感染患儿63例,根据治疗方案不同将患儿分为治疗组33例与对照组30例。2组均采用4种药物口服10d序贯疗法,即前5d予以奥美拉唑、阿莫西林—克拉维酸钾治疗,后5d予以奥美拉唑、克拉霉素及甲硝唑治疗,治疗组在开始治疗时加用亿活0.5~0.75g,每天1次,治疗10d。疗程结束后1个月采用13C尿素呼气试验评价和比较Hp根除率,治疗有效率,记录不良反应情况。结果治疗组总有效率97.0%(32/33),对照组总有效率96.7%(29/30),比较差异无统计学意义(P>0.05);治疗组Hp根除率93.94%,对照组93.8%,比较差异无统计学意义(P>0.05);治疗组不良反应发生率3.0%(1/33)低于对照组10.0%(3/30),2组比较差异有统计学意义(P<0.05)。结论亿活佐治儿童Hp感染临床效果显著,不良反应少,腹泻的症状明显改善,患者依存性好,值得临床推广。
Objective To investigate the clinical efficacy and safety of Saccharomyces cerevisiae (B) in treating children with Helicobacter pylori (Hp) infection. Methods Sixty-three children with Hp infection from April 2013 to October 2014 were selected and divided into treatment group (33 cases) and control group (30 cases) according to different treatment options. Oral injections of omeprazole and amoxicillin-clavulanate potassium in the first 5 days and omeprazole, clarithromycin and metronidazole in 5 days after treatment were used in both groups Group added 100 million live 0.5 ~ 0.75g at the beginning of treatment, once a day for 10 days. One month after the end of treatment, the 13C urea breath test was used to evaluate and compare the Hp eradication rate, the effective rate of treatment and the record of adverse reactions. Results The total effective rate was 97.0% (32/33) in the treatment group and 96.7% (29/30) in the control group, with no significant difference (P> 0.05). The Hp eradication rate was 93.94% in the treatment group and 93.8% in the control group (P> 0.05). The incidence of adverse reactions in the treatment group was 3.0% (1/33) lower than that in the control group (10.0%) (3/30), and the difference between the two groups was statistically significant (P < 0.05). Conclusion The results showed that the clinical efficacy of Hp infection in patients with active B treatment was significant, with fewer adverse reactions, significant improvement in the symptoms of diarrhea, and good clinical dependence in patients with Hp infection.